Patient characteristics
| Characteristic . | G-CSF (arm A) n = 23 . | Chemo + G-CSF (arm B) n = 24 . | Significance (95% CI) . |
|---|---|---|---|
| Age at BMT | 41 y | 46 y | 0.2 (− 12, 3) |
| Female gender | 11 (48%) | 7 (29%) | 0.24 |
| NHL | 15 (65%) | 17 (71%) | 0.7 |
| No. prior chemotherapy | |||
| 2 | 15 | 18 | 0.86 |
| 3 | 5 | 4 | |
| 4 | 2 | 2 | |
| Leukopenia* | 7 (33.3%) | 10 (47.6%) | 0.35 |
| Thrombocytopenia† | 8 (38%) | 8 (38%) | 1.0 |
| Chemoresistance at transplantation (n = 43) | 4 (19%) | 6 (28.6%) | 0.47 |
| Primary refractory disease | 8 (38%) | 4 (19%) | 0.4 |
| Characteristic . | G-CSF (arm A) n = 23 . | Chemo + G-CSF (arm B) n = 24 . | Significance (95% CI) . |
|---|---|---|---|
| Age at BMT | 41 y | 46 y | 0.2 (− 12, 3) |
| Female gender | 11 (48%) | 7 (29%) | 0.24 |
| NHL | 15 (65%) | 17 (71%) | 0.7 |
| No. prior chemotherapy | |||
| 2 | 15 | 18 | 0.86 |
| 3 | 5 | 4 | |
| 4 | 2 | 2 | |
| Leukopenia* | 7 (33.3%) | 10 (47.6%) | 0.35 |
| Thrombocytopenia† | 8 (38%) | 8 (38%) | 1.0 |
| Chemoresistance at transplantation (n = 43) | 4 (19%) | 6 (28.6%) | 0.47 |
| Primary refractory disease | 8 (38%) | 4 (19%) | 0.4 |